Business
LifeMD Expands Collaboration with Novo Nordisk as Recognized Telehealth Partner Offering Newly Approved Wegovy® Pill
Adds first and only FDA‑approved oral GLP‑1 to its virtual weight management offering, expanding access to affordable, branded treatment optionsNEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care and pharmacy services, today announced it is now offering Novo Nordisk’s Wegovy® (semaglutide) pill – the first and only FDA-approved oral GLP-1 therapy for chronic weight management and cardiovascular health – through its end-to-end telehe
About this update from Lifemd, Inc.
[{"type":"image","alt":"LifeMD, Inc.","displaySize":"","headline":null,"caption":"LifeMD, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/50005343bf87c0ac412a1713ee8f08dc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/61gLXi5OwzzXYAEyNdYSZw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/50005343bf87c0ac412a1713ee8f08dc","width":300,"height":300}},"lazy":false},{"type":"text","content":"Adds first and only FDA‑approved oral GLP‑1 to its virtual weight management offering, expanding access to affordable, branded treatment options","length":144,"tagName":"p"},{"type":"text","content":"NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care and pharmacy services, today announced it is now offering Novo Nordisk’s Wegovy® (semaglutide) pill – the first and only FDA-approved oral GLP-1 therapy for chronic weight management and cardiovascular health – through its end-to-end telehealth platform. Eligible patients can access the Wegovy® pill for as little as $149 per month, further expanding LifeMD’s portfolio of branded obesity treatments.","length":517,"tagName":"p"},{"type":"text","content":"This announcement broadens LifeMD’s long-standing collaboration with Novo Nordisk. As part of the relationship, LifeMD is featured on the NovoCare® and Wegovy® websites as a trusted telehealth provider, reflecting growing demand for convenient, clinically supported access to branded GLP-1 therapies.","length":300,"tagName":"p"},{"type":"text","content":"On December 22, 2025, the U.S. Food and Drug Administration (FDA) approved Novo Nordisk’s Wegovy® pill as the first and only oral GLP-1 therapy indicated to reduce excess body weight, support long-term weight maintenance, and reduce the risk of certain major adverse cardiovascular events.1 FDA approval of the Wegovy® pill was supported by a 64-week Phase 3 trial showing weight loss efficacy unmatched by other oral GLP-1 candidates, with once-daily treatment plus diet and exercise achieving 16.6% mean weight loss versus 2.7% with placebo.2 The availability of an oral formulation is expected to broaden access to GLP‑1 treatment by offering an alternative option for patients who may be hesitant to initiate or continue ...